Hemogenyx Pharmaceuticals Company Description
Hemogenyx Pharmaceuticals Plc, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood cancer.
The company’s lead product candidate is the HEMO-CAR-T therapy for the treatment and potential cure for relapsed and/or refractory acute myeloid leukemia.
It also develops chimeric bait receptor to treat COVID-19 virus, as well as to treat brain cancers and/or certain neurodegenerative diseases; and CDX bi-specific antibody which eliminates hematopoietic stem cells/hematopoietic progenitors in a patient using bi-specific antibodies; and cell therapy products for bone marrow/hematopoietic stem cell transplantation.
Hemogenyx Pharmaceuticals Plc was incorporated in 2013 and is headquartered in London, the United Kingdom.
| Country | United Kingdom |
| Founded | 2013 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 17 |
| CEO | Vladislav Sandler |
Contact Details
Address: 60 Gracechurch Street London, EC3V 0HR United Kingdom | |
| Website | hemogenyx.com |
Stock Details
| Ticker Symbol | HOPHF |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | GBP |
| ISIN Number | GB00BQVXM815 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Vladislav Sandler Ph.D. | Co-Founder, Chief Executive Officer and Director |
| Alexis M. Sandler J.D. | Independent Co-Founder and Non-Executive Director |
| Dr. Koen Van Besien M.D., Ph.D. | Clinical Advisor and Medical Director |